Overview

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

Status:
RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

Evaluate the efficacy safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life (HRQoL) measures in participants with Type I and Type II HAE.

Phase:

PHASE3

Details

Lead Sponsor:

ADARx Pharmaceuticals, Inc.

Treatments:

RNA, Small Interfering
Sodium Chloride